Verenium Corporation (VRNM)
Q2 2010 Earnings Call Transcript
August 9, 2010 5:00 pm ET
Kelly Lindenboom – VP, Corporate Communications
Carlos Riva – President & CEO
Janet Roemer – President & COO of Enzymes Business
Jamie Levine – EVP & CFO
Laurence Alexander – Jefferies
Pamela Bassett – Cantor Fitzgerald
Paul Resnik – Olympia Capital Markets
David Kaye [ph] – Tenor Capital [ph]
Pete Finolie [ph] – River Ridge [ph]
Thank you for holding. Welcome to Verenium's second quarter 2010 financial results conference call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being taped at the Company's request. At this time, I would like to introduce your host for today's call, Ms. Kelly Lindenboom. Ma’am, you may begin.
Thank you for joining Verenium's second quarter 2010 conference call. I'm Kelly Lindenboom, Vice President of Corporate Communications and with me today are Carlos Riva, our Chief Executive Officer; Janet Roemer, our Chief Operating Office; and Jamie Levine, our Chief Financial Officer.
The agenda for today's call is as follows
First, Carlos will review business highlights, then Janet will review key accomplishments in the Enzyme business in the second quarter of 2010, Jamie will then summarize our financial results for the second quarter of 2010 and provide financial guidance for the remainder of 2010 and we will then open the call up for your questions.
Before we begin, I would like to advise you that this discussion will include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These statements involve a high degree of risk and uncertainty and relate to matters such as our pending transaction with BP, our strategy, future operating plans, markets for our products, partnering and collaboration activities, public policy and financing activities, technical and business outlooks.